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DAS-28Abstract Aim of the work: The objectives of this study were to evaluate the use of anti-cyclic
citrullinated peptide high sensitive (anti-CCP hs) in the differentiation between rheumatoid arthritis
(RA) and chronic hepatitis C virus (HCV) associated arthropathy and its correlation with disease
activity and the degree of liver cirrhosis in RA associated with chronic HCV infection.
Patients and method: This studywas carried out on 90 chronicHCV infection patients, 90HCVneg-
ativeRApatients and90HCVpositiveRApatients, in addition to90healthy volunteers.Hepatic assess-
ment, rheumatological examination, quantitativeHCVRNAtest and abdominal ultrasonographywere
assessed in all HCV patients. Disease activity score (DAS-28) was assessed in RA patients. Erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), antinuclear antibodies (ANA), cryoglobulins,
rheumatoid factor (RF), anti-CCP3, anti-CCP hs test were assessed for all patients.
Results: The higher frequency of anti-CCP hs was found in RA (HCV+ve) (88.9%) compared to
RA (HCV-ve) (75.5%) and HCV patients (14.4%), its sensitivity in RA patients was 75.6% and speci-
ﬁcity was 85.6%. InHCVpatients anti-CCP hs signiﬁcantly correlated with cryoglobulinemia and scor-
ing for liver ﬁbrosis (p< 0.001). In RA patients, anti-CCP hs signiﬁcantly correlated with RF, anti-
CCP3, DAS-28, ESR and CRP (p< 0.001).
Conclusions: Serum anti-CCP hs is sensitive but not a speciﬁc marker for RA patients and cannot be
used as a diagnostic marker to differentiate between RA and chronic HCV associated arthropathy, in
addition it cannot be used as a marker of activity in RA especially when associated with HCV.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Rheumatoid arthritis (RA) is a chronic inﬂammatory rheu-
matic disease, in which autoantibodies are part of the early dis-
ease manifestations. It is a systemic autoimmune arthritis that
clinically manifests as joint pain, stiffness and swelling.
Persistent synovitis can progress to cartilage and bone destruc-
tion and ultimately to long-term disability [1]. Several media-
tors and factors were reported to play a role in RA patients
including cytokines [2–4], oxidative stress [5,6], angiopoietin
[7] and leptin [8].
Although the hepatitis C virus (HCV) was identiﬁed in
1989, it has emerged as a major cause not only of liver disease,
but also of numerous extra-hepatic manifestations (EHM) [9].
The rheumatologic manifestations associated with HCV infec-
tion include arthralgia, myalgia, arthritis, vasculitis, and sicca
syndrome. The articular manifestations of HCV patients range
from polyarthralgia to mono or oligoarticular intermittent
arthritis affecting large joints and symmetric chronic pol-
yarthritis which frequently display an RA-like clinical picture
[10,11]. HCV infection should be regarded as a systemic infec-
tious disease with multiorgan involvement. More than 50% of
HCV-positive patients develop during the course of the disease
at least one EHM. The EHMs are often the ﬁrst and only clin-
ical signs of a chronic HCV [12]. It has been reported to be
associated with various rheumatic diseases in Egypt as RA
[13], systemic lupus erythematosus [14] and vasculitis [15].
The anti-cyclic citrullinated peptide high sensitive (anti-
CCP hs) test detects autoantibodies against speciﬁc epitopes
of mutated citrullinated vimentin (MCV). It is thus a highly
sensitive and a very speciﬁc laboratory test for the diagnosis
of RA especially in early disease [16]. Protein citrullination
of vimentin present in hepatic stellate cells may have a role
in promoting collagen synthesis by increasing the level of col-
lagen mRNAs which may explain the ﬁbrosis seen in chronic
HCV patients [17].
This is the ﬁrst study which is concerned with a large num-
ber of Egyptian patients suffering from both chronic RA and
HCV. In sequence, the aim of our work was to study anti-
CCP hs in RA patients associated with chronic HCV and its
correlation to disease activity and liver affection in those
patients.
2. Patients and methods
2.1. Study population
This studywas carried out on 90 chronicHCV infection patients
diagnosed by HCV antibodies and conﬁrmed by polymerase
chain reaction (PCR) for detection of viral RNA. Ninety
HCV negative and 90 HCV positive RA patients fulﬁlling the
2010 American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) classiﬁcation criteria
for RA [18]. The HCV positive RA patients were erosive and
accidentally discovered to have HCV during their routine labo-
ratory investigations. All patients were recruited from the
Rheumatology and Tropical Medicine Departments, Tanta
University Hospitals, Tanta, Egypt. In addition, 90 age and
sex matched healthy volunteers were enrolled as the control
group. Patients with positive HBs Ag were excluded from the
study. Written informed consent was obtained from all patientsand healthy subjects before enrollment and the study was
approved by the local ethics committee.
2.2. Clinical examination
All HCV infected patients were thoroughly examined stressing
on hepatic and rheumatologic involvement. In RA patients,
disease activity was assessed by the disease activity for 28 joint
indices score (DAS-28) [19].
2.3. Sampling
After 12 h of overnight fasting, venous blood samples (7 ml)
were taken from all patients and controls. 1.6 ml of blood
was transferred into a vacutainer tube containing 0.4 ml
sodium citrate for erythrocyte sedimentation rate (ESR) mea-
surement. The remainder of the blood was delivered into a plain
glass tube, allowed to clot at room temperature and centrifuged
at 2000 rpm for 10 min and serum separated. Rheumatoid fac-
tor (RF) evaluation was determined immediately, and aliquots
of the serum were stored at 70 C until analysis.
2.4. Laboratory investigations
Patient and control groups underwent the following laboratory
investigations: ESR (mm/h), C-reactive protein (CRP), alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
complement-4 (C4) values, antinuclear antibody (ANA) and
cryoglobulins (CGs) were determined. Quantitative HCV
RNA test is based on the polymerase chain reaction (PCR) tech-
nique using a commercial kit (HEPA-Check-C, Nuclear Laser
Medicine, Italy) done for HCV patients. Lower limit of detec-
tion was fewer than 100 copies of HCV RNA per ml of serum
(50 IU/ml). It was classiﬁed into weak (100–100,000 IU/ml),
moderate (100,000–10,00,000) and high viraemia
(>10,00,000 IU/ml) [20]. The RF was determined by the neph-
elometry method (Behring, Marburg, Germany). Serum anti-
CCP3 was measured by ELISA (Quanta Lite CCP version 3.1
for IgG/IgA; Inova Diagnostics, San Diego, CA, USA).
Cutoff value for RF was 15.0 U/ml and for anti-CCP3 was 20
arbitrary units according to the manufacturer’s instruction.
Serum anti-CCP hs (high sensitive) test from ORGENTEC
Diagnostika quantitatively detects autoantibodies against
speciﬁc epitopes of MCV (mutated citrullinated vimentin).
ValuesP 20.0 U/ml were considered abnormal according to
the manufacturer’s recommendations. The sensitivity of the
Orgentec anti-MCV ELISA for RA was determined at
1 U/ml [21].
2.5. Abdominal ultrasonography
It was performed for HCV patients only, where liver ﬁbrosis
was evaluated by ultrasound scoring system which ranges from
4 for a normal liver to 9 or more for advanced cirrhosis [22].
Statistical analysis: All data were analyzed using SPSS soft-
ware (version11; SPSS Inc., Chicago, IL, USA). Baseline char-
acteristics are presented as mean ± standard deviation for
continuous variables, and as frequency (percentage) for dis-
crete variables. Characteristic curve analysis using cutoff val-
ues recommended by the manufacturer was used for
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anti-CCP3 and RF in RA patients. Comparisons between
groups were conducted using the ANOVA test. Fisher LSD
test was used for making comparisons for several pairs of
means. Correlation between variables was examined using
Pearson’s correlation coefﬁcient. p value < 0.05 was consid-
ered statistically signiﬁcant.3. Results
The study included 90 patients with chronic HCV and 180
patients with RA (90 with HCV+ve and 90 HCV-ve). The
main demographic and serological characteristics of RA,
HCV patients and controls are summarized in Table 1. All
HCV patients were accidentally discovered and the cause of
disease transmission was unknown, duration since discovery
of HCV infection ranged from 3 to 12 years.
As regards rheumatic manifestations in chronic HCV
patients, myalgia was detected in 40/90 (44.4%) patients, artic-
ular involvement was detected in 47/90 (52.2%) patients in the
form of diffuse polyarthralgia in 22/47 (46.8%) and arthritis in
25/47 (53.1%) patients. RA-like pattern characterized by a
non-erosive symmetric polyarthritis that affected the small
diarthrodial joint was noticed in 13/25 (52%) patients and
large joint affection of the lower limb in 12/25 (48%) patients.
No signiﬁcant difference was found between the two groups
of RA patients as regards DAS-28. ESR and CRP were signif-
icantly higher in HCV patients than in controls (p< 0.001)
and in RA patients compared to HCV patients and controls.
Signiﬁcantly higher ANA, ALT, AST and lower C4 levels were
detected in HCV and RA (HCV+ve) patients compared to
RA (HCV-ve) and controls (p< 0.001). However, there was
no signiﬁcant difference between RA (HCV-ve) patients and
controls. Detectable CGs (with acryocrit greater than 0.1%)
were found in 15/90 (16.6%) of HCV patients and in 18/90
(18.8%) of RA (HCV+ve) patients.Table 1 Demographic and serological parameters in RA and HCV
Parameters HCV patients Rheum
mean ± SD (n= 90) HCV-v
Age (years) 45.1 ± 7.3 48.2 ±
Sex (M/F) 58/32 20/70
Disease duration (years) 9.6 ± 4.3 10.3 ±
ESR (mm/h) 23.8 ± 7.9a 50.5 ±
CRP (mg/dl) 8.3 ± 4.4a 22.5 ±
ALT (U/L) 75 ± 40a 30.3 ±
AST (U/L) 108 ± 69a 33.1 ±
C4 (mg/dl) 13.9 ± 6.5a 20.5 ±
ANA (U/ml) 12.5 ± 2.9a 7.3 ±
CG n (%) 15 (16.6) –
RF (U/ml) 120.4 ± 80.3a 180 ±
Anti-CCP3 (U/ml) 15.2 ± 4.9a 323.5 ±
Anti-CCP hs (U/ml) 60.7 ± 40.5a 476.5 ±
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, ALT: al
plement 4, ANA: antinuclear antibody, CG: cryoglobulinemia, RF: rheu
a Signiﬁcantly different from the values of the control at p< 0.05.
b Signiﬁcantly different from HCV only patients at p< 0.05.
c Signiﬁcantly different from the RA (HCV-ve) patients at p< 0.05.RF and anti-CCP hs levels were signiﬁcantly higher in RA
and HCV patients than controls (p< 0.001). Moreover, their
levels were signiﬁcantly higher in RA than HCV patients and
in RA (HCV+ve) more than RA (HCV-ve). However, anti-
CCP3 levels were signiﬁcantly higher in RA than HCV
patients and controls with no signiﬁcant difference between
RA (HCV+ve) and RA (HCV-ve) patients.
The frequency of RF, anti-CCP3 and anti-CCP hs positivity
in each group of patients is presented in Table 2. No signiﬁcant
difference was shown between the prevalence of RF in the
three studied groups, its sensitivity in RA patients was
66.67% and speciﬁcity was 22.22%. However, no patient with
HCV was positive for anti-CCP3 antibodies test. Moreover,
there was no signiﬁcant difference between RA (HCV-ve)
and RA (HCV+ve) as regards prevalence of anti-CCP3 anti-
bodies, its sensitivity in RA patients was 72.22% and speci-
ﬁcity was 100%. Focusing on anti-CCP hs, it was found that
there was a signiﬁcant difference among the three studied
groups. The higher prevalence of anti-CCP hs was found in
RA (HCV+ve) compared to RA (HCV-ve) and HCV patients
(p< 0.001), its sensitivity in RA patients was 75.6% and
speciﬁcity was 85.6%.
Quantitative PCR revealed that the majority of our patients
(60%) had moderate viremia, 30% had weak and 10% high
viremia. Ultrasound scoring system of liver ﬁbrosis showed
that 87.5% of our patients had mild to moderate ﬁbrosis,
12.5% had no ﬁbrosis; while none of them had severe ﬁbrosis.
In HCV and RA (HCV+ve) patients, there was no signif-
icant correlation between RF, anti-CCP hs and anti-CCP3
levels with rheumatologic manifestations in those patients.
Anti-CCP hs signiﬁcantly correlated with cryoglobulinemia
(r= 0.6, p< 0.001) and ultrasound scoring of liver ﬁbrosis
(r= 0.49, p< 0.001). No signiﬁcant correlation was found
between anti-CCP hs and other laboratory ﬁndings or viremia
degree. In all RA patients, anti-CCP hs signiﬁcantly correlated
with RF, anti-CCP3, DAS-28, ESR and CRP (p< 0.001 for
all correlations).patients and controls.
atoid arthritis (n= 180) Controls
e (90) HCV+ve (90) (n= 90)
7.6 51.2 ± 6.4 46.5 ± 10.1
15/75 13/77
2.7 9.6 ± 2.3 –
10.8a,b 43.8 ± 13.6a,b 12.5 ± 4.9
6.6a,b 24.4 ± 5.98a,b 4.4 ± 2.7
15.1 73 ± 27a,c 32.8 ± 17.1
16.1 102 ± 47a,c 35.1 ± 15.1
8.7 14.7 ± 5.5a,c 21.5 ± 9.7
2.7 13.6 ± 3.5a,c 5.43 ± 1.9
17 (18.8) –
160.2a,b 203 ± 200.3a,b,c 14.6 ± 5.5
286.7a 305.4 ± 290.5a 14.1 ± 5.5
465.2a,b 665.7 ± 647.2a,b,c 16.1 ± 10.04
anine aminotransferase, AST: aspartate aminotransferase, C4: com-
matoid factor, Anti-CCP: anti-cyclic citrullinated peptide antibody.
Table 2 Positivity of RF, anti-CCP3 and anti-CCP hs in HCV
and RA patients.
Positivity
n (%)
HCV patients
(n= 90)
RA patients (n= 180)
HCV-ve (90) HCV+ve (90)
RF 70 (77.7) 60 (66.6) 75 (83.3)
Anti-CCP3 0 (0) 65 (72.2) 64 (71.1)
Anti-CCP hs 13 (14.4) 68 (75.5) 80 (88.9)
HCV: hepatitis C virus, RA: rheumatoid arthritis, RF: rheumatoid
factor, Anti-CCP: anti-cyclic citrullinated peptide antibody.
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The presence of EHMs particularly articular involvement is a
relatively common feature in patients with chronic hepatitis C
virus (HCV) infection. In our study myalgia was detected in
44.4% of chronic HCV patients whereas articular involvement
was detected in 52.2% of HCV patients. Most of the patients
with chronic HCV infection develop at least one extra hepatic
manifestation [23,24]. Cacoub et al. reported that EHMs are
frequently observed in patients with chronic HCV infection,
with a prevalence of more than 74% [23]. In a prospective
study on a large cohort of HCV patients, articular involvement
represented the most common EHM, affecting nearly 20% of
patients in a 1-year follow-up [24]. Whether the viral RNA is
present within the muscle ﬁbers or around them remains
unclear. However, Ito et al. [25] identiﬁed HCV RNA within
muscle ﬁbers from two symptomatic patients which suggests
a direct pathogenic link between the virus and the muscle pain.
HCV arthritis may be a part of mixed cryoglobulinemia or it
may be directly or indirectly mediated by HCV infection.
Direct invasion of synovial cells by the virus, causes local
inﬂammatory response, cytokine induced disease or immune
complex disease, particularly in genetically susceptible individ-
uals [26,27]. It is clear that the differential diagnosis between
HCV-related polyarthropathy and true RA may be very difﬁ-
cult especially with the recent onset RA before articular dam-
age and erosions develop.
Our results showed that anti-CCP3 antibodies were speciﬁc
100% for RA patients which indicate that anti-CCP3 antibod-
ies are a very strong serum marker to differentiate RA from
HCV patients. With slightly different results Se`ne et al. [28],
demonstrated the presence of anti-CCP antibodies in 5.7%
of patients with HCV-related polyarthropathy and in 78% of
patients with RA. In addition, in the study of Wener et al.
[29] anti-CCP antibodies were present in 7% of patients with
HCV-related polyarthropathy. But both of them used anti-
CCP2 antibodies which may explain that difference in our
results. In other studies comparing anti-CCP and RF for dis-
tinguishing RA and HCV patients; anti-CCP was found more
speciﬁc. RF positivity was 37.5–54% whereas anti-CCP was
positive in 0–5.7 in HCV patients. There are also a few conﬂict-
ing results concluding that anti-CCP antibodies may be
detected in HCV patients. It has been reported that some of
the anti-CCP positive patients had erosions thereby suggesting
coexistence of RA [30–33].
Mayo [34] reported that symptoms of mixed cryoglobuline-
mia are caused by vascular deposition of cryoprecipitates
which contains HCV RNA. The pathogenic role of HCV inthe cryoprecipitate has been demonstrated by selective concen-
tration of HCV and RF in the vasculitic lesions.
Anti-CCP hs was present in 14.4%, 75.5%, 88.9% in
HCV, RA (HCV-ve), RA (HCV+ve) patients respectively,
its sensitivity in RA patients was 75.56% and speciﬁcity
was 85.56%. So, its higher prevalence was found in RA
(HCV+ve) compared to RA (HCV-ve) and HCV patients.
Kaptanog˘lu et al. [35] investigated the role of anti-MCV in
HCV patients. They tested the presence of RF, anti-CCP
and anti-MCV in 34 RA and 30 HCV-infected patients.
They detected anti-MCV in 30% of HCV patients compared
to 70.6% in RA.
The formation of anti-MCV antibody in patients with
chronic hepatitis is not difﬁcult to explain. Hepatic stellate
cells contain vimentin, oxidative stress due to liver injury
can modify this vimentin so that it becomes immunogenic
stimulating the production of anti-CCP hs [16,36]. We found
also that serum concentration of anti-CCP hs antibody corre-
lated with cryoglobulinemia and the degree of liver ﬁbrosis in
patients with chronic hepatitis as it correlated with ultra-
sound grading. Abdeen et al. [37] reported the presence of
anti-MCV antibody in patients with chronic hepatitis and
have demonstrated that it can be used to diagnose liver cir-
rhosis with 60% sensitivity and speciﬁcity. They showed that
signiﬁcant protein citrullination of vimentin occurs in
patients with chronic hepatitis and that the serum concentra-
tion of anti-MCV antibody could differentiate patients with
no liver ﬁbrosis from those with moderate to severe ﬁbrosis
and this supports the theory that hepatic stellate cells play
a central role in liver ﬁbrosis.
In our study anti-CCP hs was correlated to disease activ-
ity in RA patients. Mathsson et al. [38] demonstrated the
association between a marked decrease in anti-MCV levels
and clinical improvement, which implies that it might be a
more sensitive indicator of disease activity than anti-CCP.
However, Ursum et al. [39] recorded that anti-MCV-
positive patients exhibited higher levels of inﬂammation than
those of anti-MCV-negative patients at baseline; but during
2 years of follow up, the correlation between anti-MCV levels
and measures of disease activity was very low. In another
study on 50 Egyptian RA patients, the serum anti-MCV
was signiﬁcantly elevated but there was no signiﬁcant corre-
lation with the DAS-28. However, anti-MCV signiﬁcantly
correlated with anti-CCP [40].
Fromourresultsit isobviousthatanti-CCPhs levelsarehighin
allRApatientgroupsandithasasigniﬁcantcorrelationwithanti-
CCP3anddiseaseactivityandalsocorrelatedwith liverﬁbrosis in
allHCVpatientgroups.Sowecannotuseanti-CCPhsasanactivity
marker forRAormarker for staging liverﬁbrosis inpatientswith
RA with coexistent chronic HCV. It is well known that auto-
antibodies may be positive in HCV infection without clinical
involvement. HCV infection also establishes a linkage between
extra-hepatic involvement and autoimmunity causing further
confusioninevaluatingtheautoantibodyresponses.Itisprobable
that citrullination and mutation of the vimentin encourage
autoimmunity.
In conclusion, serum anti-CCP hs is sensitive but not a
speciﬁc marker for RA patients and cannot be used as a diag-
nostic marker to differentiate between RA and chronic hepati-
tis C associated arthropathy in addition it cannot be used as a
maker of activity in RA especially when associated with hep-
atitis C virus infection.
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